

March in file

WILMER, CUTLER & PICKERING

2445 M STREET, N.W.  
WASHINGTON, D.C. 20037-1420

TELEPHONE (202) 663-6000  
FACSIMILE (202) 663-6363

100 LIGHT STREET  
BALTIMORE, MD 21202  
TELEPHONE (410) 986-2800  
FACSIMILE (410) 986-2828

4 CARLTON GARDENS  
LONDON SW1Y 5AA  
TELEPHONE 011 (44) 711 872-1000  
FACSIMILE 011 (44) 711 839-3537

RUE DE LA LOI 15 WETSTRAAT  
B-1040 BRUSSELS  
TELEPHONE 011 (32) 285-4900  
FACSIMILE 011 (32) 285-4949

FRIEDRICHSTRASSE 95  
D-10117 BERLIN  
TELEPHONE 011 (49) 301 2022-6400  
FACSIMILE 011 (49) 301 2022-6500

GARY D. WILSON  
DIRECT LINE (202) 663-6279  
INTERNET GWILSON@WILMER.COM

July 7, 1997

By Facsimile and First-Class Mail

Annette C. Hamburger  
Senior Attorney  
OGC/PHD/NIH  
Building 31, Room 2B-50  
31 Center Drive, MSC 2111  
Bethesda, MD 20895-2111



Re: Petition of CellPro, Inc.

Dear Ms. Hamburger:

Larry Culver at CellPro has pointed out to me that there were several minor errors in the estimated breakdown between commercial sales and clinical use that was submitted at Tab 5 of the Exhibit Volume that accompanied CellPro's Response of July 2, 1997. The only error that relates to U.S. sales is for fiscal year April 1, 1999, through March 31, 2000. The commercial sales estimate under the conservative sales scenario should have been 200 units less (and the clinical and other estimate should have been 200 units more) than shown. I am sending herewith a replacement exhibit marked "REVISED."

The changed exhibit necessitates a change to the text of the Response on the first line of page 4 where the number 4,120 should be 3,920. In addition, as both the original and revised exhibit make clear, there were two other small errors in the text. The sentence that carries over from page 10 to page 11 in the Response should read as follows: "CellPro projects that approximately 1000 [not 700] patients will be treated in such clinical trials in the United States between April 1, 1997, and March 31, 1998, with another 4,000 to 5,000 patients treated in ongoing or new clinical trials over the following two [not next three] years."

I apologize for the inconvenience, but would appreciate it if you would bring these corrections to the attention of Ms. McGarey, Mr. Lanman, and others involved in the review of CellPro's petition.

Very truly yours,

Gary D. Wilson

cc: Donald R. Ware  
Frederick G. Savage

REVISED

Therapeutic 12.8 Disposables  
Estimated Breakdown Between Commercial Sales and Clinical Use

	<u>1993/94</u>	<u>1994/95</u>	<u>1995/96</u>	<u>1996/97</u>	<u>1997/98</u>	<u>1998/99</u>	<u>1999/00</u>	<u>2000/01</u>
<b>Worldwide</b>								
Conservative Sales Scenario								
Commercial Sales	150	767	1155	1731	3625	6965	10705	17500
Clinical & other	<u>844</u>	<u>1180</u>	<u>1270</u>	<u>1440</u>	<u>1577</u>	<u>2950</u>	<u>3820</u>	<u>4145</u>
Total	994	1947	2425	3171	5202	9915	14525	21645
Optimistic Scenario								
Commercial Sales	150	767	1155	1731	3977	8585	15050	29250
Clinical & other	<u>844</u>	<u>1180</u>	<u>1270</u>	<u>1440</u>	<u>1687</u>	<u>3520</u>	<u>4875</u>	<u>5530</u>
Total	994	1947	2425	3171	5664	12105	19925	34780
<b>US Only</b>								
Conservative Sales Scenario								
Commercial Sales	0	0	0	20	1360	2540	3920	7000
Clinical & other	<u>649</u>	<u>906</u>	<u>970</u>	<u>1179</u>	<u>1025</u>	<u>2010</u>	<u>2790</u>	<u>2785</u>
Total	649	906	970	1199	2385	4550	6710	9785
Optimistic Scenario								
Commercial Sales	0	0	0	20	1520	3120	5520	11480
Clinical & other	<u>649</u>	<u>906</u>	<u>970</u>	<u>1179</u>	<u>1075</u>	<u>2430</u>	<u>3640</u>	<u>4160</u>
Total	649	906	970	1199	2595	5550	9160	15640